ID   RAF1_HUMAN              Reviewed;         648 AA.
AC   P04049; B0LPH8; B2R5N3; Q15278; Q9UC20;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1986, sequence version 1.
DT   10-MAY-2017, entry version 212.
DE   RecName: Full=RAF proto-oncogene serine/threonine-protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Proto-oncogene c-RAF;
DE            Short=cRaf;
DE   AltName: Full=Raf-1;
GN   Name=RAF1; Synonyms=RAF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3003687; DOI=10.1093/nar/14.2.1009;
RA   Bonner T.I., Oppermann H., Seeburg P., Kerby S.B., Gunnell M.A.,
RA   Young A.C., Rapp U.R.;
RT   "The complete coding sequence of the human raf oncogene and the
RT   corresponding structure of the c-raf-1 gene.";
RL   Nucleic Acids Res. 14:1009-1015(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LEU-308.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-308.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 228-648.
RX   PubMed=2993863; DOI=10.1128/MCB.5.6.1400;
RA   Bonner T.I., Kerby S.B., Sutrave P., Gunnell M.A., Mark G., Rapp U.R.;
RT   "Structure and biological activity of human homologs of the raf/mil
RT   oncogene.";
RL   Mol. Cell. Biol. 5:1400-1407(1985).
RN   [7]
RP   PROTEIN SEQUENCE OF 42-53; 60-65; 310-316 AND 564-572, INTERACTION
RP   WITH PRMT5, METHYLATION AT ARG-563, PHOSPHORYLATION AT SER-289;
RP   SER-296; SER-301; SER-338 AND SER-621, AND MUTAGENESIS OF ARG-563.
RX   PubMed=21917714; DOI=10.1126/scisignal.2001936;
RA   Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C.,
RA   Lopez-Fauqued M., Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R.,
RA   Canals F., Merlino G., Avila M.A., Recio J.A.;
RT   "Protein arginine methyltransferase 5 regulates ERK1/2 signal
RT   transduction amplitude and cell fate through CRAF.";
RL   Sci. Signal. 4:RA58-RA58(2011).
RN   [8]
RP   PROTEIN SEQUENCE OF 254-278, AND PHOSPHORYLATION AT THR-269.
RX   PubMed=7477354; DOI=10.1038/378307a0;
RA   Yao B., Zhang Y., Delikat S., Mathias S., Basu S., Kolesnick R.;
RT   "Phosphorylation of Raf by ceramide-activated protein kinase.";
RL   Nature 378:307-310(1995).
RN   [9]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=1886707;
RA   Dozier C., Ansieau S., Ferreira E., Coll J., Stehelin D.;
RT   "An alternatively spliced c-mil/raf mRNA is predominantly expressed in
RT   chicken muscular tissues and conserved among vertebrate species.";
RL   Oncogene 6:1307-1311(1991).
RN   [10]
RP   PHOSPHORYLATION AT SER-43; SER-259; THR-268; SER-499 AND SER-621.
RX   PubMed=8349614;
RA   Morrison D.K., Heidecker G., Rapp U.R., Copeland T.D.;
RT   "Identification of the major phosphorylation sites of the Raf-1
RT   kinase.";
RL   J. Biol. Chem. 268:17309-17316(1993).
RN   [11]
RP   INTERACTION WITH YWHAZ, AND FUNCTION.
RX   PubMed=9360956; DOI=10.1074/jbc.272.46.28882;
RA   Dubois T., Rommel C., Howell S., Steinhussen U., Soneji Y.,
RA   Morrice N., Moelling K., Aitken A.;
RT   "14-3-3 is phosphorylated by casein kinase I on residue 233.
RT   Phosphorylation at this site in vivo regulates Raf/14-3-3
RT   interaction.";
RL   J. Biol. Chem. 272:28882-28888(1997).
RN   [12]
RP   PHOSPHORYLATION.
RX   PubMed=9823899; DOI=10.1038/24184;
RA   King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S.,
RA   Marshall M.S.;
RT   "The protein kinase Pak3 positively regulates Raf-1 activity through
RT   phosphorylation of serine 338.";
RL   Nature 396:180-183(1998).
RN   [13]
RP   ERRATUM.
RA   King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S.,
RA   Marshall M.S.;
RL   Nature 406:439-439(2000).
RN   [14]
RP   PHOSPHORYLATION AT SER-259 BY PKB/AKT1, ENZYME REGULATION, AND
RP   INTERACTION WITH PKB/AKT1.
RX   PubMed=10576742; DOI=10.1126/science.286.5445.1741;
RA   Zimmermann S., Moelling K.;
RT   "Phosphorylation and regulation of Raf by Akt (protein kinase B).";
RL   Science 286:1741-1744(1999).
RN   [15]
RP   PHOSPHORYLATION AT SER-259 AND SER-621, DEPHOSPHORYLATION AT SER-43;
RP   SER-259 AND SER-621, ENZYME REGULATION, AND INTERACTION WITH PPP2CA
RP   AND PPP2R1B.
RX   PubMed=10801873; DOI=10.1074/jbc.M003259200;
RA   Abraham D., Podar K., Pacher M., Kubicek M., Welzel N., Hemmings B.A.,
RA   Dilworth S.M., Mischak H., Kolch W., Baccarini M.;
RT   "Raf-1-associated protein phosphatase 2A as a positive regulator of
RT   kinase activation.";
RL   J. Biol. Chem. 275:22300-22304(2000).
RN   [16]
RP   ENZYME REGULATION, AND PHOSPHORYLATION AT THR-491 AND SER-494.
RX   PubMed=11447113; DOI=10.1093/emboj/20.14.3716;
RA   Chong H., Lee J., Guan K.L.;
RT   "Positive and negative regulation of Raf kinase activity and function
RT   by phosphorylation.";
RL   EMBO J. 20:3716-3727(2001).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH MAP3K5/ASK1.
RX   PubMed=11427728; DOI=10.1073/pnas.141224398;
RA   Chen J., Fujii K., Zhang L., Roberts T., Fu H.;
RT   "Raf-1 promotes cell survival by antagonizing apoptosis signal-
RT   regulating kinase 1 through a MEK-ERK independent mechanism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:7783-7788(2001).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF PPP1R12A, AND INTERACTION WITH
RP   PPP1R12A.
RX   PubMed=11719507; DOI=10.1074/jbc.M106343200;
RA   Broustas C.G., Grammatikakis N., Eto M., Dent P., Brautigan D.L.,
RA   Kasid U.;
RT   "Phosphorylation of the myosin-binding subunit of myosin phosphatase
RT   by Raf-1 and inhibition of phosphatase activity.";
RL   J. Biol. Chem. 277:3053-3059(2002).
RN   [19]
RP   PHOSPHORYLATION AT SER-338 BY PAK1, ENZYME REGULATION, AND INTERACTION
RP   WITH PAK1.
RX   PubMed=11733498; DOI=10.1074/jbc.M110000200;
RA   Zang M., Hayne C., Luo Z.;
RT   "Interaction between active Pak1 and Raf-1 is necessary for
RT   phosphorylation and activation of Raf-1.";
RL   J. Biol. Chem. 277:4395-4405(2002).
RN   [20]
RP   PHOSPHORYLATION AT SER-259, DEPHOSPHORYLATION AT SER-259, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=11756411; DOI=10.1074/jbc.M108733200;
RA   Kubicek M., Pacher M., Abraham D., Podar K., Eulitz M., Baccarini M.;
RT   "Dephosphorylation of Ser-259 regulates Raf-1 membrane association.";
RL   J. Biol. Chem. 277:7913-7919(2002).
RN   [21]
RP   COMPETITION WITH RIN1.
RX   PubMed=11784866; DOI=10.1128/MCB.22.13.4638-4651.2002;
RA   Wang Y., Waldron R.T., Dhaka A., Patel A., Riley M.M., Rozengurt E.,
RA   Colicelli J.;
RT   "The RAS effector RIN1 directly competes with RAF and is regulated by
RT   14-3-3 proteins.";
RL   Mol. Cell. Biol. 22:916-926(2002).
RN   [22]
RP   ENZYME REGULATION, AND INTERACTION WITH SPRY2 AND SPRY4.
RX   PubMed=12717443; DOI=10.1038/ncb978;
RA   Sasaki A., Taketomi T., Kato R., Saeki K., Nonami A., Sasaki M.,
RA   Kuriyama M., Saito N., Shibuya M., Yoshimura A.;
RT   "Mammalian Sprouty4 suppresses Ras-independent ERK activation by
RT   binding to Raf1.";
RL   Nat. Cell Biol. 5:427-432(2003).
RN   [23]
RP   PHOSPHORYLATION AT SER-259.
RX   PubMed=15047712; DOI=10.1074/jbc.M314192200;
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RT   "LGI1, a putative tumor metastasis suppressor gene, controls in vitro
RT   invasiveness and expression of matrix metalloproteinases in glioma
RT   cells through the ERK1/2 pathway.";
RL   J. Biol. Chem. 279:23151-23157(2004).
RN   [24]
RP   ERRATUM.
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RL   J. Biol. Chem. 282:2752-2752(2007).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF ADCY2; ADCY5 AND ADCY6, AND INTERACTION
RP   WITH ADCY2; ADCY5 AND ADCY6.
RX   PubMed=15385642; DOI=10.1124/mol.66.4.;
RA   Ding Q., Gros R., Gray I.D., Taussig R., Ferguson S.S., Feldman R.D.;
RT   "Raf kinase activation of adenylyl cyclases: isoform-selective
RT   regulation.";
RL   Mol. Pharmacol. 66:921-928(2004).
RN   [26]
RP   INTERACTION WITH STK3/MST2, AND FUNCTION.
RX   PubMed=15618521; DOI=10.1126/science.1103233;
RA   O'Neill E., Rushworth L., Baccarini M., Kolch W.;
RT   "Role of the kinase MST2 in suppression of apoptosis by the proto-
RT   oncogene product Raf-1.";
RL   Science 306:2267-2270(2004).
RN   [27]
RP   INTERACTION WITH RCAN1/DSCR1.
RX   PubMed=15935327; DOI=10.1016/j.abb.2005.05.002;
RA   Cho Y.J., Abe M., Kim S.Y., Sato Y.;
RT   "Raf-1 is a binding partner of DSCR1.";
RL   Arch. Biochem. Biophys. 439:121-128(2005).
RN   [28]
RP   REVIEW ON FUNCTION.
RX   PubMed=15943972; DOI=10.1016/j.febslet.2005.03.024;
RA   Baccarini M.;
RT   "Second nature: biological functions of the Raf-1 'kinase'.";
RL   FEBS Lett. 579:3271-3277(2005).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF BAD, PHOSPHORYLATION AT SER-338 AND
RP   SER-339 BY PAK1, SUBCELLULAR LOCATION, AND INTERACTION WITH BCL2.
RX   PubMed=15849194; DOI=10.1074/jbc.M413374200;
RA   Jin S., Zhuo Y., Guo W., Field J.;
RT   "p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1
RT   regulates its mitochondrial localization, phosphorylation of BAD, and
RT   Bcl-2 association.";
RL   J. Biol. Chem. 280:24698-24705(2005).
RN   [30]
RP   PHOSPHORYLATION AT SER-471.
RX   PubMed=16093354; DOI=10.1091/mbc.E05-02-0090;
RA   Zhu J., Balan V., Bronisz A., Balan K., Sun H., Leicht D.T., Luo Z.,
RA   Qin J., Avruch J., Tzivion G.;
RT   "Identification of Raf-1 S471 as a novel phosphorylation site critical
RT   for Raf-1 and B-Raf kinase activities and for MEK binding.";
RL   Mol. Biol. Cell 16:4733-4744(2005).
RN   [31]
RP   IDENTIFICATION IN A COMPLEX WITH PP1CA; PPP1CB; PPP1CC; SHOC2 AND
RP   MRAS, PHOSPHORYLATION AT SER-259, AND CHARACTERIZATION OF VARIANT
RP   ALA-259.
RX   PubMed=16630891; DOI=10.1016/j.molcel.2006.03.027;
RA   Rodriguez-Viciana P., Oses-Prieto J., Burlingame A., Fried M.,
RA   McCormick F.;
RT   "A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic
RT   subunit of PP1 functions as an M-Ras effector to modulate Raf
RT   activity.";
RL   Mol. Cell 22:217-230(2006).
RN   [32]
RP   SUBUNIT.
RX   PubMed=16508002; DOI=10.1128/MCB.26.6.2262-2272.2006;
RA   Rushworth L.K., Hindley A.D., O'Neill E., Kolch W.;
RT   "Regulation and role of Raf-1/B-Raf heterodimerization.";
RL   Mol. Cell. Biol. 26:2262-2272(2006).
RN   [33]
RP   FUNCTION AS KINASE, ENZYME REGULATION, PHOSPHORYLATION AT SER-259;
RP   SER-338; TYR-340; TYR-341 AND SER-621, DEPHOSPHORYLATION AT SER-338 BY
RP   PPP5C, AND MUTAGENESIS OF 338-SER-SER-339; 340-TYR-TYR-341; THR-491
RP   AND SER-494.
RX   PubMed=16892053; DOI=10.1038/ncb1465;
RA   von Kriegsheim A., Pitt A., Grindlay G.J., Kolch W., Dhillon A.S.;
RT   "Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5.";
RL   Nat. Cell Biol. 8:1011-1016(2006).
RN   [34]
RP   REVIEW ON REGULATION.
RX   PubMed=17218791; DOI=10.4161/cc.6.1.3593;
RA   Dhillon A.S., von Kriegsheim A., Grindlay J., Kolch W.;
RT   "Phosphatase and feedback regulation of Raf-1 signaling.";
RL   Cell Cycle 6:3-7(2007).
RN   [35]
RP   FUNCTION.
RX   PubMed=16924233; DOI=10.1038/sj.onc.1209902;
RA   Wang Z., Wade P., Mandell K.J., Akyildiz A., Parkos C.A., Mrsny R.J.,
RA   Nusrat A.;
RT   "Raf 1 represses expression of the tight junction protein occludin via
RT   activation of the zinc-finger transcription factor slug.";
RL   Oncogene 26:1222-1230(2007).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-252, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [37]
RP   ENZYME REGULATION, AND INTERACTION WITH PEBP1/RKIP.
RX   PubMed=18294816; DOI=10.1016/j.cellsig.2008.01.012;
RA   Rath O., Park S., Tang H.H., Banfield M.J., Brady R.L., Lee Y.C.,
RA   Dignam J.D., Sedivy J.M., Kolch W., Yeung K.C.;
RT   "The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to
RT   the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated
RT   activated phosphorylation of MEK.";
RL   Cell. Signal. 20:935-941(2008).
RN   [38]
RP   PHOSPHORYLATION AT SER-338 BY PAK5.
RX   PubMed=18465753; DOI=10.1002/jcb.21809;
RA   Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.;
RT   "p21 activated kinase 5 activates Raf-1 and targets it to
RT   mitochondria.";
RL   J. Cell. Biochem. 105:167-175(2008).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [42]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19298812; DOI=10.1016/j.yexcr.2009.03.004;
RA   Smith J., Bunaciu R.P., Reiterer G., Coder D., George T., Asaly M.,
RA   Yen A.;
RT   "Retinoic acid induces nuclear accumulation of Raf1 during
RT   differentiation of HL-60 cells.";
RL   Exp. Cell Res. 315:2241-2248(2009).
RN   [43]
RP   ENZYME REGULATION, SUBUNIT, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   DGKH.
RX   PubMed=19710016; DOI=10.1074/jbc.M109.043604;
RA   Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M.,
RA   Kanoh H., Sakane F.;
RT   "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf
RT   heterodimerization.";
RL   J. Biol. Chem. 284:29559-29570(2009).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289 AND SER-301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [45]
RP   REVIEW.
RX   PubMed=20674547; DOI=10.1016/j.bbrc.2010.07.092;
RA   Roskoski R. Jr.;
RT   "RAF protein-serine/threonine kinases: structure and regulation.";
RL   Biochem. Biophys. Res. Commun. 399:313-317(2010).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [47]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [48]
RP   REVIEW.
RX   PubMed=21779496; DOI=10.1177/1947601911407323;
RA   Matallanas D., Birtwistle M., Romano D., Zebisch A., Rauch J.,
RA   von Kriegsheim A., Kolch W.;
RT   "Raf family kinases: old dogs have learned new tricks.";
RL   Genes Cancer 2:232-260(2011).
RN   [49]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [50]
RP   INTERACTION WITH FAM83B.
RX   PubMed=22886302; DOI=10.1172/JCI60517;
RA   Cipriano R., Graham J., Miskimen K.L., Bryson B.L., Bruntz R.C.,
RA   Scott S.A., Brown H.A., Stark G.R., Jackson M.W.;
RT   "FAM83B mediates EGFR- and RAS-driven oncogenic transformation.";
RL   J. Clin. Invest. 122:3197-3210(2012).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296; SER-301 AND
RP   SER-642, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [52]
RP   INTERACTION WITH PDE8A.
RX   PubMed=23509299; DOI=10.1073/pnas.1303004110;
RA   Brown K.M., Day J.P., Huston E., Zimmermann B., Hampel K.,
RA   Christian F., Romano D., Terhzaz S., Lee L.C., Willis M.J.,
RA   Morton D.B., Beavo J.A., Shimizu-Albergine M., Davies S.A., Kolch W.,
RA   Houslay M.D., Baillie G.S.;
RT   "Phosphodiesterase-8A binds to and regulates Raf-1 kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:E1533-E1542(2013).
RN   [53]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 51-131.
RX   PubMed=7791872; DOI=10.1038/375554a0;
RA   Nassar N., Horn G., Herrmann C., Scherer A., McCormick F.,
RA   Wittinghofer A.;
RT   "The 2.2 A crystal structure of the Ras-binding domain of the
RT   serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP
RT   analogue.";
RL   Nature 375:554-560(1995).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 56-131.
RX   PubMed=8756332; DOI=10.1038/nsb0896-723;
RA   Nassar N., Horn G., Herrmann C., Block C., Janknecht R.,
RA   Wittinghofer A.;
RT   "Ras/Rap effector specificity determined by charge reversal.";
RL   Nat. Struct. Biol. 3:723-729(1996).
RN   [56]
RP   STRUCTURE BY NMR OF 55-132.
RX   PubMed=7766599; DOI=10.1021/bi00021a001;
RA   Emerson S.D., Madison V.S., Palermo R.E., Waugh D.S., Scheffler J.E.,
RA   Tsao K.L., Kiefer S.E., Liu S.P., Fry D.C.;
RT   "Solution structure of the Ras-binding domain of c-Raf-1 and
RT   identification of its Ras interaction surface.";
RL   Biochemistry 34:6911-6918(1995).
RN   [57]
RP   STRUCTURE BY NMR OF 136-187.
RX   PubMed=8710867; DOI=10.1073/pnas.93.16.8312;
RA   Mott H.R., Carpenter J.W., Zhong S., Ghosh S., Bell R.M.,
RA   Campbell S.L.;
RT   "The solution structure of the Raf-1 cysteine-rich domain: a novel ras
RT   and phospholipid binding site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:8312-8317(1996).
RN   [58]
RP   VARIANTS NS5 SER-256; PHE-259; ARG-260; LEU-261; SER-261; ASN-486;
RP   GLY-486; ILE-491; ARG-491 AND THR-612, VARIANT HYPERTROPHIC
RP   CARDIOMYOPATHY ILE-260, VARIANTS LPRD2 LEU-257 AND VAL-613, VARIANT
RP   NS5 LEU-257, CHARACTERIZATION OF VARIANTS NS5 SER-261; ASN-486 AND
RP   ILE-491, AND CHARACTERIZATION OF VARIANT LPRD2 VAL-613.
RX   PubMed=17603483; DOI=10.1038/ng2073;
RA   Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K.,
RA   Martinelli S., Pogna E.A., Schackwitz W., Ustaszewska A.,
RA   Landstrom A., Bos J.M., Ommen S.R., Esposito G., Lepri F., Faul C.,
RA   Mundel P., Lopez Siguero J.P., Tenconi R., Selicorni A., Rossi C.,
RA   Mazzanti L., Torrente I., Marino B., Digilio M.C., Zampino G.,
RA   Ackerman M.J., Dallapiccola B., Tartaglia M., Gelb B.D.;
RT   "Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes
RT   with hypertrophic cardiomyopathy.";
RL   Nat. Genet. 39:1007-1012(2007).
RN   [59]
RP   VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND VAL-613, AND
RP   CHARACTERIZATION OF VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263
RP   AND VAL-613.
RX   PubMed=17603482; DOI=10.1038/ng2078;
RA   Razzaque M.A., Nishizawa T., Komoike Y., Yagi H., Furutani M., Amo R.,
RA   Kamisago M., Momma K., Katayama H., Nakagawa M., Fujiwara Y.,
RA   Matsushima M., Mizuno K., Tokuyama M., Hirota H., Muneuchi J.,
RA   Higashinakagawa T., Matsuoka R.;
RT   "Germline gain-of-function mutations in RAF1 cause Noonan syndrome.";
RL   Nat. Genet. 39:1013-1017(2007).
RN   [60]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-259 AND HIS-335.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [61]
RP   VARIANT NS5 SER-261.
RX   PubMed=20683980; DOI=10.1002/ajmg.a.33564;
RA   Longoni M., Moncini S., Cisternino M., Morella I.M., Ferraiuolo S.,
RA   Russo S., Mannarino S., Brazzelli V., Coi P., Zippel R., Venturin M.,
RA   Riva P.;
RT   "Noonan syndrome associated with both a new Jnk-activating familial
RT   SOS1 and a de novo RAF1 mutations.";
RL   Am. J. Med. Genet. A 152:2176-2184(2010).
RN   [62]
RP   INVOLVEMENT IN CMD1NN, VARIANTS CMD1NN THR-237; ALA-310; ALA-332;
RP   PRO-603; ARG-626 AND MET-641, AND CHARACTERIZATION OF VARIANTS CMD1NN
RP   THR-237; ALA-310; ALA-332; PRO-603; ARG-626 AND MET-641.
RX   PubMed=24777450; DOI=10.1038/ng.2963;
RA   Dhandapany P.S., Razzaque M.A., Muthusami U., Kunnoth S.,
RA   Edwards J.J., Mulero-Navarro S., Riess I., Pardo S., Sheng J.,
RA   Rani D.S., Rani B., Govindaraj P., Flex E., Yokota T., Furutani M.,
RA   Nishizawa T., Nakanishi T., Robbins J., Limongelli G., Hajjar R.J.,
RA   Lebeche D., Bahl A., Khullar M., Rathinavel A., Sadler K.C.,
RA   Tartaglia M., Matsuoka R., Thangaraj K., Gelb B.D.;
RT   "RAF1 mutations in childhood-onset dilated cardiomyopathy.";
RL   Nat. Genet. 46:635-639(2014).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts as a
CC       regulatory link between the membrane-associated Ras GTPases and
CC       the MAPK/ERK cascade, and this critical regulatory link functions
CC       as a switch determining cell fate decisions including
CC       proliferation, differentiation, apoptosis, survival and oncogenic
CC       transformation. RAF1 activation initiates a mitogen-activated
CC       protein kinase (MAPK) cascade that comprises a sequential
CC       phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and
CC       MAP2K2/MEK2) and the extracellular signal-regulated kinases
CC       (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on
CC       residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-
CC       antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl
CC       cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation.
CC       Phosphorylates PPP1R12A resulting in inhibition of the phosphatase
CC       activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can
CC       promote NF-kB activation and inhibit signal transducers involved
CC       in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2),
CC       proliferation and angiogenesis (RB1). Can protect cells from
CC       apoptosis also by translocating to the mitochondria where it binds
CC       BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates
CC       Rho signaling and migration, and is required for normal wound
CC       healing. Plays a role in the oncogenic transformation of
CC       epithelial cells via repression of the TJ protein, occludin (OCLN)
CC       by inducing the up-regulation of a transcriptional repressor
CC       SNAI2/SLUG, which induces down-regulation of OCLN. Restricts
CC       caspase activation in response to selected stimuli, notably Fas
CC       stimulation, pathogen-mediated macrophage apoptosis, and erythroid
CC       differentiation. {ECO:0000269|PubMed:11427728,
CC       ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642,
CC       ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,
CC       ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233,
CC       ECO:0000269|PubMed:9360956}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 2 Zn(2+) ions per subunit.;
CC   -!- ENZYME REGULATION: Regulation is a highly complex process
CC       involving membrane recruitment, protein-protein interactions,
CC       dimerization, and phosphorylation/dephosphorylation events. Ras-
CC       GTP recruits RAF1 to the membrane, thereby promoting its
CC       activation. The inactive conformation of RAF1 is maintained by
CC       autoinhibitory interactions occurring between the N-terminal
CC       regulatory and the C-terminal catalytic domains and by the binding
CC       of a 14-3-3 protein that contacts two phosphorylation sites, Ser-
CC       259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1A
CC       cooperate to release autoinhibition and the subsequent
CC       phosphorylation of activating sites: Ser-338, Tyr-341, Thr-491,
CC       and Ser-494, yields a fully active kinase. Through a negative
CC       feedback mechanism involving MAPK1/ERK2, RAF1 is phosphorylated on
CC       Ser-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 by
CC       MAPK1/ERK2, which yields an inactive, desensitized kinase. The
CC       signaling-competent conformation of RAF1 is finally re-established
CC       by the coordinated action of PIN1, a prolyl isomerase that
CC       converts pSer and pThr residues from the cis to the trans
CC       conformation, which is preferentially recognized and
CC       dephosphorylated by PPP2R1A. Activated by homodimerization and
CC       heterodimerization (with BRAF). Also regulated through association
CC       with other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP,
CC       PHB/prohibitin and SPRY4. PEBP1/RKIP acts by dissociating RAF1
CC       from its substrates MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitin
CC       facilitates the displacement of 14-3-3 from RAF1 by activated Ras,
CC       thereby promoting cell membrane localization and phosphorylation
CC       of RAF1 at the activating Ser-338. SPRY4 inhibits Ras-independent,
CC       but not Ras-dependent, activation of RAF1. CNKSR1/CNK1 regulates
CC       Src-mediated RAF1 activation. {ECO:0000269|PubMed:10576742,
CC       ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113,
CC       ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:12717443,
CC       ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18294816,
CC       ECO:0000269|PubMed:19710016}.
CC   -!- SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and this
CC       heterodimer possesses a highly increased kinase activity compared
CC       to the respective homodimers or monomers (PubMed:16508002).
CC       Heterodimerization is mitogen-regulated and enhanced by 14-3-3
CC       proteins (PubMed:16508002). MAPK1/ERK2 activation can induce a
CC       negative feedback that promotes the dissociation of the
CC       heterodimer (PubMed:16508002). Forms a multiprotein complex with
CC       Ras (M-Ras/MRAS), SHOC2 and protein phosphatase 1 (PPP1CA, PPP1CB
CC       and PPP1CC) (PubMed:16630891). Interacts with Ras proteins; the
CC       interaction is antagonized by RIN1 (PubMed:11784866). Weakly
CC       interacts with RIT1. Interacts (via N-terminus) with RGS14 (via
CC       RBD domains); the interaction mediates the formation of a ternary
CC       complex with BRAF, a ternary complex inhibited by GNAI1 (By
CC       similarity). Interacts with STK3/MST2; the interaction inhibits
CC       its pro-apoptotic activity (PubMed:15618521). Interacts (when
CC       phosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-
CC       232') (PubMed:9360956). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2
CC       (By similarity). Interacts with MAP3K5/ASF1 (via N-terminus) and
CC       this interaction inhibits the proapoptotic function of MAP3K5/ASK1
CC       (PubMed:11427728). Interacts with PAK1 (via kinase domain)
CC       (PubMed:11733498). The phosphorylated form interacts with PIN1 (By
CC       similarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1)
CC       interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIP
CC       and this interaction is enhanced if RAF1 is phosphorylated on
CC       residues Ser-338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816).
CC       Interacts with ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A,
CC       PKB/AKT1, PPP2CA, PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 and
CC       PHB/prohibitin (PubMed:10801873, PubMed:11719507, PubMed:12717443,
CC       PubMed:15385642, PubMed:15935327, PubMed:19710016,
CC       PubMed:10576742). Interacts with ROCK2 (By similarity). In its
CC       active form, interacts with PRMT5 (PubMed:21917714). Interacts
CC       with FAM83B; displaces 14-3-3 proteins from RAF1 and activates
CC       RAF1 (PubMed:22886302). Interacts with PDE8A; the interaction
CC       promotes RAF1 activity (PubMed:23509299).
CC       {ECO:0000250|UniProtKB:P11345, ECO:0000250|UniProtKB:Q99N57,
CC       ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,
CC       ECO:0000269|PubMed:11427728, ECO:0000269|PubMed:11719507,
CC       ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11784866,
CC       ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:15385642,
CC       ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,
CC       ECO:0000269|PubMed:15935327, ECO:0000269|PubMed:16508002,
CC       ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:18294816,
CC       ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:21917714,
CC       ECO:0000269|PubMed:22886302, ECO:0000269|PubMed:23509299,
CC       ECO:0000269|PubMed:9360956}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-365996, EBI-365996;
CC       P31749:AKT1; NbExp=2; IntAct=EBI-365996, EBI-296087;
CC       Q92934:BAD; NbExp=2; IntAct=EBI-365996, EBI-700771;
CC       P15056:BRAF; NbExp=46; IntAct=EBI-365996, EBI-365980;
CC       P49368:CCT3; NbExp=3; IntAct=EBI-365996, EBI-356673;
CC       P30304:CDC25A; NbExp=4; IntAct=EBI-365996, EBI-747671;
CC       Q16543:CDC37; NbExp=4; IntAct=EBI-365996, EBI-295634;
CC       P31327:CPS1; NbExp=4; IntAct=EBI-365996, EBI-536811;
CC       P01112:HRAS; NbExp=14; IntAct=EBI-365996, EBI-350145;
CC       P08238:HSP90AB1; NbExp=3; IntAct=EBI-365996, EBI-352572;
CC       P11021:HSPA5; NbExp=4; IntAct=EBI-365996, EBI-354921;
CC       P01116-2:KRAS; NbExp=2; IntAct=EBI-365996, EBI-367427;
CC       P28301:Lox (xeno); NbExp=2; IntAct=EBI-365996, EBI-642911;
CC       Q02750:MAP2K1; NbExp=31; IntAct=EBI-365996, EBI-492564;
CC       P36507:MAP2K2; NbExp=3; IntAct=EBI-365996, EBI-1056930;
CC       Q9ESN9-2:Mapk8ip3 (xeno); NbExp=2; IntAct=EBI-365996, EBI-9549291;
CC       Q12968:NFATC3; NbExp=2; IntAct=EBI-365996, EBI-5278441;
CC       P03495:NS (xeno); NbExp=2; IntAct=EBI-365996, EBI-2548993;
CC       O39474:NS5A (xeno); NbExp=4; IntAct=EBI-365996, EBI-7016711;
CC       O43482:OIP5; NbExp=4; IntAct=EBI-365996, EBI-536879;
CC       Q13177:PAK2; NbExp=2; IntAct=EBI-365996, EBI-1045887;
CC       P09619:PDGFRB; NbExp=2; IntAct=EBI-365996, EBI-641237;
CC       P30086:PEBP1; NbExp=7; IntAct=EBI-365996, EBI-716384;
CC       Q96S96:PEBP4; NbExp=4; IntAct=EBI-365996, EBI-8563667;
CC       P14618:PKM; NbExp=3; IntAct=EBI-365996, EBI-353408;
CC       P62834:RAP1A; NbExp=2; IntAct=EBI-365996, EBI-491414;
CC       P01120:RAS2 (xeno); NbExp=2; IntAct=EBI-365996, EBI-14838;
CC       P06400:RB1; NbExp=3; IntAct=EBI-365996, EBI-491274;
CC       P53805-2:RCAN1; NbExp=4; IntAct=EBI-365996, EBI-1541912;
CC       P31947:SFN; NbExp=3; IntAct=EBI-365996, EBI-476295;
CC       Q3ZCQ8:TIMM50; NbExp=4; IntAct=EBI-365996, EBI-355175;
CC       P31946:YWHAB; NbExp=18; IntAct=EBI-365996, EBI-359815;
CC       P62258:YWHAE; NbExp=3; IntAct=EBI-365996, EBI-356498;
CC       Q04917:YWHAH; NbExp=6; IntAct=EBI-365996, EBI-306940;
CC       P27348:YWHAQ; NbExp=3; IntAct=EBI-365996, EBI-359854;
CC       P63104:YWHAZ; NbExp=13; IntAct=EBI-365996, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion.
CC       Nucleus. Note=Colocalizes with RGS14 and BRAF in both the
CC       cytoplasm and membranes. Phosphorylation at Ser-259 impairs its
CC       membrane accumulation. Recruited to the cell membrane by the
CC       active Ras protein. Phosphorylation at Ser-338 and Ser-339 by PAK1
CC       is required for its mitochondrial localization. Retinoic acid-
CC       induced Ser-621 phosphorylated form of RAF1 is predominantly
CC       localized at the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=6C;
CC         IsoId=P04049-1; Sequence=Displayed;
CC       Name=2; Synonyms=1A;
CC         IsoId=P04049-2; Sequence=VSP_034649;
CC   -!- TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundant
CC       than isoform 2. {ECO:0000269|PubMed:1886707}.
CC   -!- PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 and
CC       Ser-494 results in its activation. Phosphorylation at Ser-29, Ser-
CC       43, Ser-289, Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results in
CC       its inactivation. Phosphorylation at Ser-259 induces the
CC       interaction with YWHAZ and inactivates kinase activity.
CC       Dephosphorylation of Ser-259 by the complex containing protein
CC       phosphatase 1, SHOC2 and M-Ras/MRAS relieves inactivation, leading
CC       to stimulate RAF1 activity. Phosphorylation at Ser-338 by PAK1 and
CC       PAK5 and Ser-339 by PAK1 is required for its mitochondrial
CC       localization. Phosphorylation at Ser-621 in response to growth
CC       factor treatment stabilizes the protein, possibly by preventing
CC       proteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-
CC       301, Ser-338 and Ser-621 are somehow linked to the methylation
CC       potential of cells. Treatment of cells with HGF in the presence of
CC       the methylation inhibitor 5'-methylthioadenosine (MTA) results in
CC       increased phosphorylation at Ser-338 and Ser-621 and decreased
CC       phosphorylation at Ser-296, Ser-301 and Ser-338. Dephosphorylation
CC       at Ser-338 by PPP5C results in a activity decrease.
CC       {ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,
CC       ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498,
CC       ECO:0000269|PubMed:11756411, ECO:0000269|PubMed:15047712,
CC       ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16093354,
CC       ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:16892053,
CC       ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714,
CC       ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614,
CC       ECO:0000269|PubMed:9823899}.
CC   -!- PTM: Methylated at Arg-563 in response to EGF treatment. This
CC       modification leads to destabilization of the protein, possibly
CC       through proteasomal degradation. {ECO:0000269|PubMed:21917714}.
CC   -!- DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan
CC       syndrome, a disease characterized by short stature, facial
CC       dysmorphic features such as hypertelorism, a downward eyeslant and
CC       low-set posteriorly rotated ears, and a high incidence of
CC       congenital heart defects and hypertrophic cardiomyopathy. Other
CC       features can include a short neck with webbing or redundancy of
CC       skin, deafness, motor delay, variable intellectual deficits,
CC       multiple skeletal defects, cryptorchidism, and bleeding diathesis.
CC       Individuals with Noonan syndrome are at risk of juvenile
CC       myelomonocytic leukemia, a myeloproliferative disorder
CC       characterized by excessive production of myelomonocytic cells.
CC       {ECO:0000269|PubMed:17603482, ECO:0000269|PubMed:17603483,
CC       ECO:0000269|PubMed:20683980}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder
CC       characterized by lentigines, electrocardiographic conduction
CC       abnormalities, ocular hypertelorism, pulmonic stenosis,
CC       abnormalities of genitalia, retardation of growth, and
CC       sensorineural deafness. {ECO:0000269|PubMed:17603483}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A
CC       disorder characterized by ventricular dilation and impaired
CC       systolic function, resulting in congestive heart failure and
CC       arrhythmia. Patients are at risk of premature death.
CC       {ECO:0000269|PubMed:24777450}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. RAF subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/raf1/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RAF1ID42032ch3p25.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X03484; CAA27204.1; -; mRNA.
DR   EMBL; AY271661; AAP03432.1; -; Genomic_DNA.
DR   EMBL; AK312248; BAG35180.1; -; mRNA.
DR   EMBL; EU332868; ABY87557.1; -; Genomic_DNA.
DR   EMBL; CH471055; EAW64134.1; -; Genomic_DNA.
DR   EMBL; BC018119; AAH18119.1; -; mRNA.
DR   EMBL; L00212; AAA60247.1; -; Genomic_DNA.
DR   EMBL; L00206; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00207; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00208; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00209; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00210; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00211; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00213; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; M11376; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; X54851; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS2612.1; -. [P04049-1]
DR   PIR; A00637; TVHUF6.
DR   PIR; S60341; S60341.
DR   RefSeq; NP_002871.1; NM_002880.3. [P04049-1]
DR   RefSeq; XP_005265412.1; XM_005265355.2. [P04049-1]
DR   RefSeq; XP_011532276.1; XM_011533974.2. [P04049-1]
DR   UniGene; Hs.159130; -.
DR   PDB; 1C1Y; X-ray; 1.90 A; B=55-131.
DR   PDB; 1FAQ; NMR; -; A=136-187.
DR   PDB; 1FAR; NMR; -; A=136-187.
DR   PDB; 1GUA; X-ray; 2.00 A; B=51-131.
DR   PDB; 1RFA; NMR; -; A=55-132.
DR   PDB; 3CU8; X-ray; 2.40 A; P/Q=256-264.
DR   PDB; 3IQJ; X-ray; 1.15 A; P=255-264.
DR   PDB; 3IQU; X-ray; 1.05 A; P=255-260.
DR   PDB; 3IQV; X-ray; 1.20 A; P=255-260.
DR   PDB; 3KUC; X-ray; 1.92 A; B=51-131.
DR   PDB; 3KUD; X-ray; 2.15 A; B=51-131.
DR   PDB; 3NKX; X-ray; 2.40 A; P/Q=255-264.
DR   PDB; 3O8I; X-ray; 2.00 A; B=255-264.
DR   PDB; 3OMV; X-ray; 4.00 A; A/B=323-618.
DR   PDB; 4FJ3; X-ray; 1.95 A; P=229-264.
DR   PDB; 4G0N; X-ray; 2.45 A; B=54-131.
DR   PDB; 4G3X; X-ray; 3.25 A; B=55-131.
DR   PDB; 4IEA; X-ray; 1.70 A; P=618-625.
DR   PDB; 4IHL; X-ray; 2.20 A; P=229-264.
DR   PDBsum; 1C1Y; -.
DR   PDBsum; 1FAQ; -.
DR   PDBsum; 1FAR; -.
DR   PDBsum; 1GUA; -.
DR   PDBsum; 1RFA; -.
DR   PDBsum; 3CU8; -.
DR   PDBsum; 3IQJ; -.
DR   PDBsum; 3IQU; -.
DR   PDBsum; 3IQV; -.
DR   PDBsum; 3KUC; -.
DR   PDBsum; 3KUD; -.
DR   PDBsum; 3NKX; -.
DR   PDBsum; 3O8I; -.
DR   PDBsum; 3OMV; -.
DR   PDBsum; 4FJ3; -.
DR   PDBsum; 4G0N; -.
DR   PDBsum; 4G3X; -.
DR   PDBsum; 4IEA; -.
DR   PDBsum; 4IHL; -.
DR   DisProt; DP00171; -.
DR   ProteinModelPortal; P04049; -.
DR   SMR; P04049; -.
DR   BioGrid; 111831; 159.
DR   DIP; DIP-1048N; -.
DR   IntAct; P04049; 111.
DR   MINT; MINT-86694; -.
DR   STRING; 9606.ENSP00000251849; -.
DR   BindingDB; P04049; -.
DR   ChEMBL; CHEMBL1906; -.
DR   DrugBank; DB08912; Dabrafenib.
DR   DrugBank; DB05268; iCo-007.
DR   DrugBank; DB04973; LErafAON.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB05190; XL281.
DR   GuidetoPHARMACOLOGY; 2184; -.
DR   iPTMnet; P04049; -.
DR   PhosphoSitePlus; P04049; -.
DR   BioMuta; RAF1; -.
DR   DMDM; 125651; -.
DR   EPD; P04049; -.
DR   MaxQB; P04049; -.
DR   PaxDb; P04049; -.
DR   PeptideAtlas; P04049; -.
DR   PRIDE; P04049; -.
DR   DNASU; 5894; -.
DR   Ensembl; ENST00000251849; ENSP00000251849; ENSG00000132155. [P04049-1]
DR   Ensembl; ENST00000442415; ENSP00000401888; ENSG00000132155. [P04049-2]
DR   GeneID; 5894; -.
DR   KEGG; hsa:5894; -.
DR   UCSC; uc003bxf.5; human. [P04049-1]
DR   CTD; 5894; -.
DR   DisGeNET; 5894; -.
DR   GeneCards; RAF1; -.
DR   GeneReviews; RAF1; -.
DR   HGNC; HGNC:9829; RAF1.
DR   HPA; CAB019291; -.
DR   HPA; HPA002640; -.
DR   MalaCards; RAF1; -.
DR   MIM; 164760; gene.
DR   MIM; 611553; phenotype.
DR   MIM; 611554; phenotype.
DR   MIM; 615916; phenotype.
DR   neXtProt; NX_P04049; -.
DR   OpenTargets; ENSG00000132155; -.
DR   Orphanet; 154; Familial isolated dilated cardiomyopathy.
DR   Orphanet; 500; LEOPARD syndrome.
DR   Orphanet; 648; Noonan syndrome.
DR   Orphanet; 251612; Pilocytic astrocytoma.
DR   PharmGKB; PA34183; -.
DR   eggNOG; KOG0193; Eukaryota.
DR   eggNOG; ENOG410Y4UP; LUCA.
DR   GeneTree; ENSGT00760000118807; -.
DR   HOGENOM; HOG000252972; -.
DR   HOVERGEN; HBG001886; -.
DR   InParanoid; P04049; -.
DR   KO; K04366; -.
DR   OMA; DGPSCIS; -.
DR   OrthoDB; EOG091G09SB; -.
DR   PhylomeDB; P04049; -.
DR   TreeFam; TF317006; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-2672351; Stimuli-sensing channels.
DR   Reactome; R-HSA-392517; Rap1 signalling.
DR   Reactome; R-HSA-430116; GP1b-IX-V activation signalling.
DR   Reactome; R-HSA-442742; CREB phosphorylation through the activation of Ras.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway.
DR   Reactome; R-HSA-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802949; Signaling by RAS mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   SignaLink; P04049; -.
DR   SIGNOR; P04049; -.
DR   ChiTaRS; RAF1; human.
DR   EvolutionaryTrace; P04049; -.
DR   GeneWiki; C-Raf; -.
DR   GenomeRNAi; 5894; -.
DR   PMAP-CutDB; P04049; -.
DR   PRO; PR:P04049; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000132155; -.
DR   CleanEx; HS_RAF1; -.
DR   ExpressionAtlas; P04049; baseline and differential.
DR   Genevisible; P04049; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IPI:MGI.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:ProtInc.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0031143; C:pseudopodium; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; IBA:GO_Central.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; NAS:BHF-UCL.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:AgBase.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0030154; P:cell differentiation; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0071550; P:death-inducing signaling complex assembly; IEA:Ensembl.
DR   GO; GO:0060324; P:face development; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0035773; P:insulin secretion involved in cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0045104; P:intermediate filament cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0034220; P:ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0007275; P:multicellular organism development; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; TAS:UniProtKB.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0031333; P:negative regulation of protein complex assembly; IDA:UniProtKB.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IBA:GO_Central.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IBA:GO_Central.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; TAS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:0035023; P:regulation of Rho protein signal transduction; TAS:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0030878; P:thyroid gland development; IEA:Ensembl.
DR   GO; GO:0042060; P:wound healing; TAS:UniProtKB.
DR   CDD; cd00029; C1; 1.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR003116; RBD_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF02196; RBD; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00455; RBD; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50898; RBD; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cardiomyopathy;
KW   Cell membrane; Complete proteome; Cytoplasm; Deafness;
KW   Direct protein sequencing; Disease mutation; Kinase; Membrane;
KW   Metal-binding; Methylation; Mitochondrion; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Zinc; Zinc-finger.
FT   CHAIN         1    648       RAF proto-oncogene serine/threonine-
FT                                protein kinase.
FT                                /FTId=PRO_0000086596.
FT   DOMAIN       56    131       RBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00262}.
FT   DOMAIN      349    609       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING     138    184       Phorbol-ester/DAG-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     355    363       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      331    349       Interaction with PEBP1/RKIP.
FT   ACT_SITE    468    468       Proton acceptor.
FT   METAL       139    139       Zinc 1.
FT   METAL       152    152       Zinc 2.
FT   METAL       155    155       Zinc 2.
FT   METAL       165    165       Zinc 1.
FT   METAL       168    168       Zinc 1.
FT   METAL       173    173       Zinc 2.
FT   METAL       176    176       Zinc 2.
FT   METAL       184    184       Zinc 1.
FT   BINDING     375    375       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      29     29       Phosphoserine; by MAPK1. {ECO:0000250}.
FT   MOD_RES      43     43       Phosphoserine; by PKA and MAPK1.
FT                                {ECO:0000269|PubMed:8349614}.
FT   MOD_RES     233    233       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:9823899}.
FT   MOD_RES     252    252       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332}.
FT   MOD_RES     259    259       Phosphoserine; by PKA, PKC and PKB/AKT1.
FT                                {ECO:0000269|PubMed:10576742,
FT                                ECO:0000269|PubMed:10801873,
FT                                ECO:0000269|PubMed:11756411,
FT                                ECO:0000269|PubMed:15047712,
FT                                ECO:0000269|PubMed:16630891,
FT                                ECO:0000269|PubMed:16892053,
FT                                ECO:0000269|PubMed:8349614}.
FT   MOD_RES     268    268       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8349614}.
FT   MOD_RES     269    269       Phosphothreonine; by PKA.
FT                                {ECO:0000269|PubMed:7477354}.
FT   MOD_RES     289    289       Phosphoserine; by MAPK1.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:21917714}.
FT   MOD_RES     296    296       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     301    301       Phosphoserine; by MAPK1.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21917714}.
FT   MOD_RES     338    338       Phosphoserine; by PAK1, PAK2, PAK3 and
FT                                PAK5. {ECO:0000269|PubMed:11733498,
FT                                ECO:0000269|PubMed:15849194,
FT                                ECO:0000269|PubMed:16892053,
FT                                ECO:0000269|PubMed:18465753,
FT                                ECO:0000269|PubMed:21917714}.
FT   MOD_RES     339    339       Phosphoserine; by PAK1, PAK2 and PAK3.
FT                                {ECO:0000269|PubMed:15849194}.
FT   MOD_RES     340    340       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:16892053}.
FT   MOD_RES     341    341       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:16892053}.
FT   MOD_RES     471    471       Phosphoserine.
FT                                {ECO:0000269|PubMed:16093354}.
FT   MOD_RES     491    491       Phosphothreonine.
FT                                {ECO:0000269|PubMed:11447113}.
FT   MOD_RES     494    494       Phosphoserine.
FT                                {ECO:0000269|PubMed:11447113}.
FT   MOD_RES     497    497       Phosphoserine; by PKC.
FT                                {ECO:0000269|PubMed:9823899}.
FT   MOD_RES     499    499       Phosphoserine; by PKC.
FT                                {ECO:0000269|PubMed:8349614}.
FT   MOD_RES     563    563       Symmetric dimethylarginine; by PRMT5.
FT                                {ECO:0000269|PubMed:21917714}.
FT   MOD_RES     621    621       Phosphoserine.
FT                                {ECO:0000269|PubMed:10801873,
FT                                ECO:0000269|PubMed:16892053,
FT                                ECO:0000269|PubMed:21917714,
FT                                ECO:0000269|PubMed:8349614}.
FT   MOD_RES     642    642       Phosphoserine; by MAPK1.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     278    278       E -> ENNNLSASPRAWSRRFCLRGR (in isoform
FT                                2). {ECO:0000305}.
FT                                /FTId=VSP_034649.
FT   VARIANT     237    237       A -> T (in CMD1NN; shows a mild increase
FT                                in kinase activity; dbSNP:rs587777588).
FT                                {ECO:0000269|PubMed:24777450}.
FT                                /FTId=VAR_071844.
FT   VARIANT     256    256       R -> S (in NS5; dbSNP:rs397516826).
FT                                {ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037807.
FT   VARIANT     257    257       S -> L (in NS5 and LPRD2; shows in vitro
FT                                greater kinase activity and enhanced ERK
FT                                activation than wild-type;
FT                                dbSNP:rs80338796).
FT                                {ECO:0000269|PubMed:17603482,
FT                                ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037808.
FT   VARIANT     259    259       S -> A (in an ovarian serous carcinoma
FT                                sample; somatic mutation; increased ERK
FT                                activation).
FT                                {ECO:0000269|PubMed:16630891,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041037.
FT   VARIANT     259    259       S -> F (in NS5).
FT                                {ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037809.
FT   VARIANT     260    260       T -> I (in hypertrophic cardiomyopathy;
FT                                dbSNP:rs869025501).
FT                                {ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037810.
FT   VARIANT     260    260       T -> R (in NS5).
FT                                {ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037811.
FT   VARIANT     261    261       P -> A (in NS5; shows in vitro greater
FT                                kinase activity and enhanced MAPK1
FT                                activation than wild-type;
FT                                dbSNP:rs121434594).
FT                                {ECO:0000269|PubMed:17603482}.
FT                                /FTId=VAR_037812.
FT   VARIANT     261    261       P -> L (in NS5; shows greater kinase
FT                                activity and enhanced MAPK1 activation
FT                                than wild-type; dbSNP:rs397516828).
FT                                {ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037813.
FT   VARIANT     261    261       P -> S (in NS5; shows in vitro greater
FT                                kinase activity and enhanced MAPK1
FT                                activation than wild-type;
FT                                dbSNP:rs121434594).
FT                                {ECO:0000269|PubMed:17603482,
FT                                ECO:0000269|PubMed:17603483,
FT                                ECO:0000269|PubMed:20683980}.
FT                                /FTId=VAR_037814.
FT   VARIANT     263    263       V -> A (in NS5; shows in vitro greater
FT                                kinase activity and enhanced MAPK1
FT                                activation than wild-type).
FT                                {ECO:0000269|PubMed:17603482}.
FT                                /FTId=VAR_037815.
FT   VARIANT     308    308       P -> L (in dbSNP:rs5746220).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018840.
FT   VARIANT     310    310       T -> A (in CMD1NN; shows a mild increase
FT                                in kinase activity; dbSNP:rs778155315).
FT                                {ECO:0000269|PubMed:24777450}.
FT                                /FTId=VAR_071845.
FT   VARIANT     332    332       P -> A (in CMD1NN; shows a mild increase
FT                                in kinase activity).
FT                                {ECO:0000269|PubMed:24777450}.
FT                                /FTId=VAR_071846.
FT   VARIANT     335    335       Q -> H (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041038.
FT   VARIANT     486    486       D -> G (in NS5; dbSNP:rs397516815).
FT                                {ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037816.
FT   VARIANT     486    486       D -> N (in NS5; has reduced or absent
FT                                kinase activity; dbSNP:rs80338798).
FT                                {ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037817.
FT   VARIANT     491    491       T -> I (in NS5; has reduced or absent
FT                                kinase activity; dbSNP:rs80338799).
FT                                {ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037818.
FT   VARIANT     491    491       T -> R (in NS5; dbSNP:rs80338799).
FT                                {ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037819.
FT   VARIANT     603    603       L -> P (in CMD1NN; shows impaired kinase
FT                                activity and reduced MAPK3 activation
FT                                with this mutation; dbSNP:rs587777586).
FT                                {ECO:0000269|PubMed:24777450}.
FT                                /FTId=VAR_071847.
FT   VARIANT     612    612       S -> T (in NS5).
FT                                {ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037820.
FT   VARIANT     613    613       L -> V (in NS5 and LPRD2; shows in vitro
FT                                greater kinase activity and enhanced
FT                                MAPK1 activation than wild-type;
FT                                dbSNP:rs80338797).
FT                                {ECO:0000269|PubMed:17603482,
FT                                ECO:0000269|PubMed:17603483}.
FT                                /FTId=VAR_037821.
FT   VARIANT     626    626       H -> R (in CMD1NN; shows a mild increase
FT                                in kinase activity).
FT                                {ECO:0000269|PubMed:24777450}.
FT                                /FTId=VAR_071848.
FT   VARIANT     641    641       T -> M (in CMD1NN; shows a mild increase
FT                                in kinase activity; dbSNP:rs587777587).
FT                                {ECO:0000269|PubMed:24777450}.
FT                                /FTId=VAR_071849.
FT   MUTAGEN     338    339       SS->AA: Reduced kinase activity; when
FT                                associated with 340-D-D-341.
FT                                {ECO:0000269|PubMed:16892053}.
FT   MUTAGEN     338    339       SS->DE: Non-inhibited by PPP5C.
FT                                Constitutively active and non-inhibited
FT                                by PPP5C; when associated with 340-D-D-
FT                                341. {ECO:0000269|PubMed:16892053}.
FT   MUTAGEN     340    341       YY->DD: Constitutively active and highly
FT                                phosphorylated on S-338, inhibited by
FT                                PPP5C. Reduced kinase activity; when
FT                                associated with 338-A-A-339.
FT                                Constitutively active and non-inhibited
FT                                by PPP5C; when associated with 338-D-E-
FT                                339. {ECO:0000269|PubMed:16892053}.
FT   MUTAGEN     491    491       T->D: Increased kinase activity but can
FT                                still be inhibited by PPP5C; when
FT                                associated with D-494.
FT                                {ECO:0000269|PubMed:16892053}.
FT   MUTAGEN     494    494       S->D: Increased kinase activity but can
FT                                still be inhibited by PPP5C; when
FT                                associated with D-491.
FT                                {ECO:0000269|PubMed:16892053}.
FT   MUTAGEN     563    563       R->K: Loss of methylation. Increased
FT                                stability and catalytic activity in
FT                                response to EGF treatment.
FT                                {ECO:0000269|PubMed:21917714}.
FT   CONFLICT    240    240       F -> L (in Ref. 6; AAA60247).
FT                                {ECO:0000305}.
FT   CONFLICT    542    542       M -> I (in Ref. 6; AAA60247).
FT                                {ECO:0000305}.
FT   STRAND       57     62       {ECO:0000244|PDB:1C1Y}.
FT   TURN         63     65       {ECO:0000244|PDB:1C1Y}.
FT   STRAND       66     71       {ECO:0000244|PDB:1C1Y}.
FT   HELIX        78     87       {ECO:0000244|PDB:1C1Y}.
FT   TURN         88     90       {ECO:0000244|PDB:1C1Y}.
FT   HELIX        93     95       {ECO:0000244|PDB:1C1Y}.
FT   STRAND       96    102       {ECO:0000244|PDB:1C1Y}.
FT   HELIX       103    105       {ECO:0000244|PDB:1C1Y}.
FT   STRAND      106    112       {ECO:0000244|PDB:1C1Y}.
FT   HELIX       118    121       {ECO:0000244|PDB:1C1Y}.
FT   STRAND      125    130       {ECO:0000244|PDB:1C1Y}.
FT   STRAND      142    144       {ECO:0000244|PDB:1FAQ}.
FT   STRAND      155    159       {ECO:0000244|PDB:1FAQ}.
FT   STRAND      161    164       {ECO:0000244|PDB:1FAQ}.
FT   TURN        166    169       {ECO:0000244|PDB:1FAQ}.
FT   HELIX       174    176       {ECO:0000244|PDB:1FAR}.
FT   STRAND      177    182       {ECO:0000244|PDB:1FAQ}.
SQ   SEQUENCE   648 AA;  73052 MW;  EF821B5349711BC3 CRC64;
     MEHIQGAWKT ISNGFGFKDA VFDGSSCISP TIVQQFGYQR RASDDGKLTD PSKTSNTIRV
     FLPNKQRTVV NVRNGMSLHD CLMKALKVRG LQPECCAVFR LLHEHKGKKA RLDWNTDAAS
     LIGEELQVDF LDHVPLTTHN FARKTFLKLA FCDICQKFLL NGFRCQTCGY KFHEHCSTKV
     PTMCVDWSNI RQLLLFPNST IGDSGVPALP SLTMRRMRES VSRMPVSSQH RYSTPHAFTF
     NTSSPSSEGS LSQRQRSTST PNVHMVSTTL PVDSRMIEDA IRSHSESASP SALSSSPNNL
     SPTGWSQPKT PVPAQRERAP VSGTQEKNKI RPRGQRDSSY YWEIEASEVM LSTRIGSGSF
     GTVYKGKWHG DVAVKILKVV DPTPEQFQAF RNEVAVLRKT RHVNILLFMG YMTKDNLAIV
     TQWCEGSSLY KHLHVQETKF QMFQLIDIAR QTAQGMDYLH AKNIIHRDMK SNNIFLHEGL
     TVKIGDFGLA TVKSRWSGSQ QVEQPTGSVL WMAPEVIRMQ DNNPFSFQSD VYSYGIVLYE
     LMTGELPYSH INNRDQIIFM VGRGYASPDL SKLYKNCPKA MKRLVADCVK KVKEERPLFP
     QILSSIELLQ HSLPKINRSA SEPSLHRAAH TEDINACTLT TSPRLPVF
//
